Dr. Stephen Finn
Associate Professor Consultant, Histopathology
Biography
Dr. Stephen Finn MB BAO BCh FDS PhD FRCPath FFPATH, is a Associate Professor, Consultant Pathologist and Principal Investigator at The University of Dublin, Trinity College and at St. James's Hospital Dublin, a tertiary referral cancer institution. He is co-director of the Cancer Molecular Diagnostic Laboratory, the only fully accredited molecular diagnostic laboratory in Ireland. His clinical practice is limited to Urological, Gastrointestinal and Liver pathology. Dr. Finn is former Senior Scientist and Staff Pathologist to the Centre for Molecular Oncologic Pathology at the Dana Farber Cancer Institute, Boston, USA. Dr. Finn continues to have strong personal and collaborative links to the Harvard School of Public Health, the Dana Farber Cancer Institute and the University of Orebro in Sweden. Dr. Finn is a member of the Irish Prostate Cancer Research Consortium (PCRC) and the Transdisciplinary Prostate Cancer Partnership ToPCaP. Dr. Finn, a current recipient of the Prostate Cancer Foundation Young investigator Award, and is committed to forging a career as an independent researcher focused on prostate cancer and bringing his skills as a clinician, pathologist and scientist to bear on critical questions of clinical relevance to men who suffer from aggressive prostate cancer.
Publications and Further Research Outputs
Peer-Reviewed Publications
Baird AM, Finn SP, Gray SG, Sheils O., Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma., Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 16, (1), 2021, p14-16
Bracken-Clarke D, Kapoor D, Baird AM, Buchanan PJ, Gately K, Cuffe S, Finn SP., Vaping and lung cancer - A review of current data and recommendations., Lung cancer (Amsterdam, Netherlands), 153, 2021, p11-20
Pernar CH, Parmigiani G, Giovannucci EL, Rimm EB, Tyekucheva S, Loda M, Finn SP, Vander Heiden MG, Fiorentino M, Ebot EM, Mucci LA., Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer., Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021
Oner E, Kotmakci M, Baird AM, Gray SG, Debelec Butuner B, Bozkurt E, Kantarci AG, Finn SP., Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids., Journal of nanobiotechnology, 19, (71), 2021, p1-20
Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, Mucci LA., Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer., Clinical cancer research : an official journal of the American Association for Cancer Research, 26, (5), 2020, p1086-1093
Malone T, Schäfer L, Simon N, Heavey S, Cuffe S, Finn S, Moore G, Gately K., Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer., Pharmacology and Therapeutics, 207, 2020
Ta R, Santini C, Gou P, Lee G, Tai YC, O'Brien C, Fontecha M, Grant C, Bacon L, Finn S, Vandenberghe E, Quinn F, Dua R, Flavin R., Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay , J Mol Diagn, 2020, pS1525-1578-
Brady L, Hayes B, Sheill G, Baird AM, Guinan E, Stanfill B, Vlajnic T, Casey O, Murphy V, Greene J, Allott EH, Hussey J, Cahill F, Van Hemelrijck M, Peat N, Mucci L, Cunningham M, Grogan L, Lynch T, Manecksha RP, McCaffrey J, O'Donnell D, Sheils O, O'Leary J, Rudman S, McDermott R, Finn S., Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial., PloS one, 15, (12), 2020, pe0243928
O'Gorman P, Naimimohasses S, Monaghan A, Kennedy M, Melo AM, Ní Fhloinn D, Doherty DG, Beddy P, Finn SP, Moore JB, Gormley J, Norris S. , Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention, Alimentary Pharmacology and Therapeutics, 52, (8), 2020, p1387-1398
Stopsack KH, Gerke T, Zareba P, Pettersson A, Chowdhury D, Ebot EM, Flavin R, Finn S, Kantoff PW, Stampfer MJ, Loda M, Fiorentino M, Mucci LA., Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer., Carcinogenesis, 41, (7), 2020, p904-908
O'Gorman P, Naimimohasses S, Monaghan A, Kennedy M, Finn SP, Moore JB, Gormley J, Norris S, Letter: proving the benefit of exercise intervention in metabolic associated fatty liver disease-authors' reply., Alimentary pharmacology & therapeutics, 2020
Hashim D, Gonzalez-Feliciano AG, Ahearn TU, Pettersson A, Barber L, Pernar CH, Ebot EM, Isikbay M, Finn SP, Giovannucci EL, Lis RT, Loda M, Parmigiani G, Lotan T, Kantoff PW, Mucci LA, Graff RE., Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer., International journal of cancer, 146, (10), 2020, p2694-2702
Tonry C, Finn S, Armstrong J, Pennington SR., Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management., Clinical proteomics, 17, (1), 2020, p41
Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Tsourti Z, Geiger T, Kammler R, Peters S, Stahel RA; European Thoracic Oncology Platform Lungscape Consortium., Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort., Modern Pathology, 33, (5), 2020, p792 - 801
Flynn L*, Barr MP*, Baird AM*, Smyth P, Casey OM, Blackshields G, Greene J, Pennington SR, Hams E, Fallon PG, O'Leary JJ, Sheils O, Finn SP. , Prostate cancer-derived holoclones: a novel and effective model for evaluating cancer stemness., Scientific Reports, 10, (1), 2020, p11329-
Silva R, Moran B, Russell NM, Fahey C, Vlajnic T, Manecksha RP, Finn SP, Brennan DJ, Gallagher WM, Perry AS., Evaluating liquid biopsies for methylomic profiling of prostate cancer., Epigenetics, 15, (6-7), 2020, p715-727
Ryan, S.-L. and Beard, S. and Barr, M.P. and Umezawa, K. and Heavey, S. and Godwin, P. and Gray, S.G. and Cormican, D. and Finn, S.P. and Gately, K.A. and Davies, A.M. and Thompson, E.W. and Richard, D.J. and O'Byrne, K.J. and Adams, M.N. and Baird, A.-M., Targeting NF-KB-mediated inflammatory pathways in cisplatin-resistant NSCLC, Lung Cancer, 135, 2019, p217-227
O'Reilly E, Tuzova AV, Walsh AL, Russell NM, O'Brien O, Kelly S, Dhomhnallain ON, DeBarra L, Dale CM, Brugman R, Clarke G, Schmidt O, O'Meachair S, Patil D, Pellegrini KL, Fleshner N, Garcia J, Zhao F, Finn S, Mills R, Hanna MY, Hurst R, McEvoy E, Gallagher WM, Manecksha RP, Cooper CS, Brewer DS, Bapat B, Sanda MG, Clark J, Perry AS., epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer., JCO Precis Oncol, 2019, 2019
Greene J, Baird AM, Casey O, Brady L, Blackshields G, Lim M, O'Brien O, Gray SG, McDermott R, Finn SP., Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide., Scientific reports, 9, (1), 2019, p10739
O'Brien O, Wright MC, O'Brien C, Geoghegan O, Leonard N, Nicholson S, Cuffe S, Fabre A, Jochum W, Joerger M, Gray SG, Finn SP., Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples., Diagnostics (Basel), 9, (1), 2019
Dziadziuszko R, Smit EF, Dafni U, Wolf J, Was"g B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters S., Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)., Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 14, (6), 2019, p1086-1094
Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG., When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?, Frontiers in endocrinology, 10, 2019, p89
Kerr K.M, Thunnissen E, Dafni U, Finn S.P, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel E.-J.M, Pokharel S, Quinn A.M, Monkhorst K, Navarro A, Madsen L.B, Radonic T, Wilson J, De Luca G, Gray S.G, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans A.-M, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R, A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project, Lung Cancer, 131, 2019, p95 - 103
Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L, Plymate SR, Praet SFE, Guinan EM, Van Blarigan EL, Casey O, Buzza M, Gledhill S, Zhang L, Galvão DA, Ryan CJ, Saad F., Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol., BMJ Open, 8, (5), 2018
Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, Cuffe S, Finn SP, O'Byrne KJ, Gately K., Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines., Scientific Reports, 8, (1), 2018, p1652-
Lim MCJ, Baird AM, Aird J, Greene J, Kapoor D, Gray SG, McDermott R, Finn SP., RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer-From Cell Line Models to Liquid Biopsies., Diagnostics (Basel), 8, (3), 2018
MacDonagh, L. and Gray, S.G. and Breen, E. and Cuffe, S. and Finn, S.P. and O'Byrne, K.J. and Barr, M.P., BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC, Cancer Letters, 428, 2018, p117-126
Konrad H. Stopsack, Amparo G. Gonzalez-Feliciano, Samuel F. Peisch, Mary K. Downer, Riley A. Gage, Stephen Finn, Rosina T. Lis, Rebecca E. Graff, Andreas Pettersson, Claire H. Pernar, Massimo Loda, Philip W. Kantoff, Thomas U. Ahearn, Lorelei A. Mucci, A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status, Cancer Epidemiology Biomarkers & Prevention, 2018, pcebp.0510.2018
Pernar CH, Ebot EM, Pettersson A, Graff RE, Giunchi F, Ahearn TU, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Stopsack KH, Gazeeva E, Lis RT, Parmigiani G, Rimm EB, Finn SP, Giovannucci EL, Fiorentino M, Mucci LA., A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG., European urology, 2018
John Aird, Anne-Marie Baird, Marvin C.J. Lim, Ray McDermott, Stephen P. Finn, Steven G. Gray, Carcinogenesis in prostate cancer: The role of long non-coding RNAs, Non-coding RNA Research, 3, (1), 2018, p29--38
Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A., Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort., Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13, (12), 2018, p1851-1863
Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S, ETOP Lungscape Consortium., Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project., Annals of oncology : official journal of the European Society for Medical Oncology, 29, (1), 2018, p200-208
Bubendorf Lukas, Dafni Urania, Schöbel Martin, Finn Stephen P, Tischler Verena, Sejda Aleksandra, Marchetti Antonio, Thunnissen Erik, Verbeken Eric K, Warth Arne, Sansano Irene, Cheney Richard, Speel Ernst Jan M, Nonaka Daisuke, Monkhorst Kim, Hager Henrik, Martorell Miguel, Savic Spasenija, Kerr Keith M, Tan Qiang, Tsourti Zoi, Geiger Thomas R, Kammler Roswitha, Schulze Katja, Das-Gupta Ashis, Shames David, Peters Solange, Stahel Rolf A, =Lungscape Consortium, Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project , Lung cancer (Amsterdam, Netherlands) , 111 , 2017, p143 - 149
Sheill, Gráinne and Brady, Lauren and Guinan, Emer and Hayes, Brian and Casey, Orla and Greene, John and Vlajnic, Tatjana and Cahill, Fidelma and Van Hemelrijck, Mieke and Peat, Nicola and Rudman, Sarah and Hussey, Juliette and Cunningham, Moya and Grogan, Liam and Lynch, Thomas and Manecksha, Rustom P and McCaffrey, John and Mucci, Lorelei and Sheils, Orla and O'Leary, John and O'Donnell, Dearbhaile M and McDermott, Ray and Finn, Stephen, The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial, Trials, 18, (1), 2017, p456
MacDonagh Lauren, Gallagher Michael F, Ffrench Brendan, Gasch Claudia, Breen Eamon, Gray Steven G, Nicholson Siobhan, Leonard Niamh, Ryan Ronan, Young Vincent, O'Leary John J, Cuffe Sinead, Finn Stephen P, O'Byrne Kenneth J, Barr Martin P, Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC , Oncotarget , 8 , (42 ), 2017, p72544 - 72563
Ebot Ericka M, Gerke Travis, Labbé David P, Sinnott Jennifer A, Zadra Giorgia, Rider Jennifer R, Tyekucheva Svitlana, Wilson Kathryn M, Kelly Rachel S, Shui Irene M, Loda Massimo, Kantoff Philip W, Finn Stephen, Vander Heiden Matthew G, Brown Myles, Giovannucci Edward L, Mucci Lorelei A, Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer , Cancer , 123 , (21 ), 2017, p4130 - 4138
Inder, S., O'Rourke, S., McDermott, N., (...), Lynch, T., Marignol, L. , The Notch-3 receptor: A molecular switch to tumorigenesis?, Cancer treatment reviews, 60, 2017, p69-76
Letovanec Igor, Finn Stephen, Zygoura Panagiota, Smyth Paul, Soltermann Alex, Bubendorf Lukas, Speel Ernst-Jan, Marchetti Antonio, Nonaka Daisuke, Monkhorst Kim, Hager Henrik, Martorell Miguel, Sejda Aleksandra, Cheney Richard, Hernandez-Losa Javier, Verbeken Eric, Weder Walter, Savic Spasenija, Di Lorito Alessia, Navarro Atilio, Felip Enriqueta, Warth Arne, Baas Paul, Meldgaard Peter, Blackhall Fiona, Dingemans Anne-Marie, Dienemann Hendrik, Dziadziuszko Rafal, Vansteenkiste Johan, O'Brien Cathal, Geiger Thomas, Sherlock Jon, Schageman Jeoffrey, Dafni Urania, Kammler Roswitha, Kerr Keith, Thunnissen Erik, Stahel Rolf, Peters Solange, =ETOP Lungscape Consortium, Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: Results from the ETOP Lungscape Project , Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer , 2017
Greene John, Baird Anne-Marie, Brady Lauren, Lim Marvin, Gray Steven G, McDermott Raymond, Finn Stephen P, Circular RNAs: Biogenesis, Function and Role in Human Diseases , Frontiers in molecular biosciences , 4 , 2017, p38 -
Tyekucheva Svitlana, Bowden Michaela, Bango Clyde, Giunchi Francesca, Huang Ying, Zhou Chensheng, Bondi Arrigo, Lis Rosina, Van Hemelrijck Mieke, Andrén Ove, Andersson Sven-Olof, Watson R William, Pennington Stephen, Finn Stephen P, Martin Neil E, Stampfer Meir J, Parmigiani Giovanni, Penney Kathryn L, Fiorentino Michelangelo, Mucci Lorelei A, Loda Massimo, Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer , Nature communications , 8 , (1 ), 2017, p420 -
Quinn Leah, Gray Steven G, Meaney Steve, Finn Stephen, McLoughlin Padraig, Hayes Maria, Extraction and Quantification of Sinapinic Acid from Irish Rapeseed Meal and Assessment of Angiotensin-I Converting Enzyme (ACE-I) Inhibitory Activity , Journal of agricultural and food chemistry , 65 , (32 ), 2017, p6886 - 6892
Heery Richard, Finn Stephen P, Cuffe Sinead, Gray Steven G, Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells , Cancers , 9 , (4 ), 2017, p38-
Breen Kieran J, O'Neill Amanda, Murphy Lisa, Fan Yue, Boyce Susie, Fitzgerald Noel, Dorris Emma, Brady Lauren, Finn Stephen P, Hayes Brian D, Treacy Ann, Barrett Ciara, Aziz Mardiana Abdul, Kay Elaine W, Fitzpatrick John M, Watson R William G, Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery , The Prostate , 77 , (12 ), 2017, p1288 - 1300
Zareba Piotr, Flavin Richard, Isikbay Masis, Rider Jennifer R, Gerke Travis A, Finn Stephen, Pettersson Andreas, Giunchi Francesca, Unger Robert H, Tinianow Alex M, Andersson Swen-Olof, Andren Ove, Fall Katja, Fiorentino Michelangelo, Mucci Lorelei A, =Transdisciplinary Prostate Cancer Partnership (ToPCaP), Perineural Invasion and Risk of Lethal Prostate Cancer , Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology , 26 , (5 ), 2017, p719 - 726
Prichard David O, Byrne Anne Marie, Murphy James O, Reynolds John V, O'Sullivan Jacintha, Feighery Ronan, Doyle Brendan, Eldin Osama Sharaf, Finn Stephen P, Maguire Aoife, Duff Deirdre, Kelleher Dermot P, Long Aideen, Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin-αv trafficking , Journal of cellular and molecular medicine , 21 , (12 ), 2017, p3612 - 3625
Dowling CatrÃona M, Hayes Sheri L, Phelan James J, Cathcart Mary Clare, Finn Stephen P, Mehigan Brian, McCormick Paul, Coffey John C, O'sullivan Jacintha, Kiely Patrick A, Expression of protein kinase C gamma promotes cell migration in colon cancer , Oncotarget , 8 , (42 ), 2017, p72096 - 72107
Staunton Lisa, Tonry Claire, Lis Rosina, Espina Virginia, Liotta Lance, Inzitari Rosanna, Bowden Michaela, Fabre Aurelie, O'Leary John, Finn Stephen P, Loda Massimo, Pennington Stephen R, Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment , Molecular cancer research : MCR , 15 , (3 ), 2017, p281 - 293
Cregan S, Breslin M, Roche G, Wennstedt S, MacDonagh L, Albadri C, Gao Y, O'Byrne K.J, Cuffe S, Finn S.P, Gray S.G, Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma, International Journal of Oncology, 50, (3), 2017, p1044 - 1052
Hallinan N, Finn S, Cuffe S, Rafee S, O'Byrne K, Gately K, Targeting the fibroblast growth factor receptor family in cancer, Cancer Treatment Reviews, 46, 2016, p51 - 62
Leon, G., MacDonagh, L., Finn, S.P., Cuffe, S., Barr, M.P., Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways, Pharmacology and Therapeutics, 158, 2016, p71 - 90
Markt Sarah C, Nuttall Elizabeth, Turman Constance, Sinnott Jennifer, Rimm Eric B, Ecsedy Ethan, Unger Robert H, Fall Katja, Finn Stephen, Jensen Majken K, Rider Jennifer R, Kraft Peter, Mucci Lorelei A, Sniffing out significant "Pee values": genome wide association study of asparagus anosmia , BMJ (Clinical research ed.) , 355 , 2016, pi6071 -
O'Reilly VP, Wong L, Kennedy C, Elliot LA, O'Meachair S, Coughlan AM, O'Brien EC, Ryan MM, Sandoval D, Connolly E, Dekkema GJ, Lau J, Abdulahad WH, Sanders JS, Heeringa P, Buckley C, O'Brien C, Finn S, Cohen CD, Lindemeyer MT, Hickey FB, O'Hara PV, Feighery C, Moran SM, Mellotte G, Clarkson MR, Dorman AJ, Murray PT, Little MA., Urinary Soluble CD163 in Active Renal Vasculitis., Journal of the American Society of Nephrology, 27, (9), 2016, p2906 - 2916
MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP, Lung cancer stem cells: The root of resistance., 2016
Staunton, L., Tonry, C., Lis, R., Finn, S., O'Leary, J., Loda, M., Bowden, M., Pennington, S.R., Profiling the tumor microenvironment proteome in prostate cancer using laser capture microdissection coupled to LC-MS-A technical report, EuPA Open Proteomics, 10, 2016, p19-23
Joerger, M., Finn, S.P., Cuffe, S., Byrne, A.T., Gray, S.G., The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?, Expert Opinion on Therapeutic Targets, 20, (11), 2016, 1339-1356
Ahearn, T.U., Tchrakian, N., Wilson, K.M., Lis, R., Nuttall, E., Sesso, H.D., Loda, M., Giovannucci, E., Mucci, L.A., Finn, S., Shui, I.M., Calcium-sensing receptor tumor expression and lethal prostate cancer progression, Journal of Clinical Endocrinology and Metabolism, 101, (6), 2016, p2520-2527
Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG, KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma., International journal of oncology, 48, (3), 2016, p1290-6
Heavey S, Cuffe S, Finn S, Young V, Ryan R, Nicholson S, Leonard N, McVeigh N, Barr M, O'Byrne K, Gately K, In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC, Oncotarget, 7, (48), 2016, p79526 - 79543
Cregan S, McDonagh L, Gao Y, Barr MP, O'Byrne KJ, Finn SP, Cuffe S, Gray SG, KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma., International Journal of Oncology, 48, (3), 2016, p1290-1296
Gray, S.G., Cuffe, S., Finn, S.P., PD-L1 as a companion biomarker for immune checkpoint inhibitors in NSCLC: Should RNA ISH (RISH) be considered?, Journal of Thoracic Oncology, 11, (11), 2016, e142-e144
Tonry Claire L, Leacy Emma, Raso Cinzia, Finn Stephen P, Armstrong John, Pennington Stephen R, The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer , Diagnostics (Basel, Switzerland) , 6 , (3 ), 2016
Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, Rider JR, Fiorentino M, Finn S, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Mucci LA, Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression., 2016
Hayes, B.D., Brady, L., Pollak, M., Finn, S.P., Exercise and prostate cancer: Evidence and proposed mechanisms for disease modification, Cancer Epidemiology Biomarkers and Prevention, 25, (9), 2016, p1281-1288
MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, Barr MP, Lung cancer stem cells: The root of resistance., Cancer letters, 372, (2), 2016, p147-56
van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients., 2015
Rider, J.R., Fiorentino, M., Kelly, R., Gerke, T., Jordahl, K., Sinnott, J.A., Giovannucci, E.L., Loda, M., Mucci, L.A., Finn, S., Tumor expression of adiponectin receptor 2 and lethal prostate cancer, Carcinogenesis, 36, (6), 2015, p639-647
Lochrin, S.E., Figg, W.D., Finn, S.P., Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance, Cancer Biology and Therapy, 16, (2), 2015, p201-203
Anne-Marie Byrne , Spiros Bekiaris, Gina Duggan, David Prichard, Murat Kirca, Stephen Finn, John V Reynolds, Dermot Kelleher and Aideen Long, Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion, British Journal of Cancer, 113, 2015, p1332-1342
Quinn, L., Finn, S.P., Cuffe, S., Gray, S.G., Non-coding RNA repertoires in malignant pleural mesothelioma, Lung Cancer, 90, (3), 2015, p417-426
Martin, N.E., Gerke, T., Sinnott, J.A., Stack, E.C., Andren, O., Andersson, S.-O., Johansson, J.-E., Fiorentino, M., Finn, S., Fedele, G., Stampfer, M., Kantoff, P.W., Mucci, L.A., Loda, M., Measuring PI3K activation: Clinicopathologic, immunohistochemical, and RNA expression analysis in prostate cancer, Molecular Cancer Research, 13, (10), 2015, p1431-1440
Quinn L, Finn SP, Cuffe S, Gray SG, Non-coding RNA repertoires in malignant pleural mesothelioma., Lung cancer (Amsterdam, Netherlands), 90, (3), 2015, p417-26
Stahel, R., Bogaerts, J., Ciardiello, F., de Ruysscher, D., Dubsky, P., Ducreux, M., Finn, S., Laurent-Puig, P., Peters, S., Piccart, M., Smit, E., Sotiriou, C., Tejpar, S., Van Cutsem, E., Tabernero, J., Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development, Cancer Treatment Reviews, 41, (2), 2015, p129-135
Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL, A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer., Journal of the National Cancer Institute, 108, (2), 2015
MacDonagh,Lauren , Gray,Steven George, Finn,Stephen P. , Cuffe,Sinead D. , O'Byrne,Kenneth John, Barr,Martin P. , The emerging role of microRNAs in resistance to lung cancer treatments, Cancer Treatment Reviews, 41, (2), 2015, p160-169
Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA, Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters., Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 9, (11), 2014, p1675-84
Seiwert, T.Y., Wang, X., Heitmann, J., Villegas-Bergazzi, V., Sprott, K., Finn, S., O'Regan, E., Farrow, A.D., Weichselbaum, R.R., Lingen, M.W., Cohen, E.E.W., Stenson, K., Weaver, D.T., Vokes, E.E., DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer, PLoS ONE, 9, (7), 2014
d'Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, Haley K, Kernan N, Murphy C, Smyth PC, O'Byrne K, Pennington S, Cooke AA, Ffrench B, Martin CM, O'Donnell D, Hennessy B, Stordal B, Finn S, McCann A, Gleeson N, D'Arcy T, Flood B, O'Neill LA, Sheils O, O'Toole S, O'Leary JJ, The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer., PloS one, 9, (6), 2014, pe100816
O'Brien CP, Langabeer SE, O'Byrne KJ, O'Leary JJ, Finn SP, Predictive values for molecular diagnostics: converting unknown unknowns to known unknowns., Molecular diagnosis & therapy, 18, (1), 2014, p1-4
Hayes BD, Finn SP, Kidney volume correlates with tumor diameter in renal cell carcinoma and is associated with histological poor prognostic features., International journal of surgical pathology, 22, (1), 2014, p39-46
Nur MM, Finn S, Reynolds JV, Identification of potential therapeutic molecular targets preferentially expressed by esophageal cancer cells., Expert review of anticancer therapy, 14, (3), 2014, p267-9
Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, Finn SP, O'Byrne KJ, Gately K, Strategic targeting of the PI3K-NF"B axis in cisplatin-resistant NSCLC., Cancer biology & therapy, 15, (10), 2014, p1367-77
O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ, Barr MP., The role of DNA repair pathways in cisplatin resistant lung cancer, Cancer Treatment Reviews, 40, (10), 2014, p1161 - 1170
O'Brien CP, Finn SP, Application of statistical process control to qualitative molecular diagnostic assays., Frontiers in molecular biosciences, 1, 2014, p18
Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA, SPINK1 protein expression and prostate cancer progression., Clinical cancer research : an official journal of the American Association for Cancer Research, 20, (18), 2014, p4904-11
O'Brien CP, Taylor SE, O'Leary JJ, Finn SP, Molecular testing in oncology: Problems, pitfalls and progress., Lung cancer (Amsterdam, Netherlands), 2014
Shikhrakab H, Elamin YY, O'Brien C, Gately K, Finn S, O'Byrne K, Osman N, Epidermal growth factor receptor (EGFR) mutation testing, from bench to practice: a single institute experience., Irish medical journal, 107, (7), 2014, p201-4
Fitzpatrick, J.M., Bellmunt, J., Fizazi, K., Heidenreich, A., Sternberg, C.N., Tombal, B., Alcaraz, A., Bahl, A., Bracarda, S., Di Lorenzo, G., Efstathiou, E., Finn, S.P., Fosså, S., Gillessen, S., Kellokumpu-Lehtinen, P.-L., Lecouvet, F.E., Oudard, S., De Reijke, T.M., Robson, C.N., De Santis, M., Seruga, B., De Wit, R., Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel, European Journal of Cancer, 50, (9), 2014, p1617-1627
Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjö A, Rouleau E, Solé F, Thunnissen E, Timens W, Schuuring E, Dequeker E, Murray S, Dietel M, Groenen P, Van Krieken JH, European Society of Pathology Task Force on Quality Assurance in Molecular Pathology, Royal College of Pathologists, Guidance for laboratories performing molecular pathology for cancer patients., 2014
Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E, Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study., Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 22, (11), 2013, p1984-93
Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, Fiorentino M, Gleason grade progression is uncommon., Cancer research, 73, (16), 2013, p5163-8
Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D'Arcy T, d'Adhemar C, Norris L, Langhe R, Saadeh FA, O'Leary JJ, O'Toole SA, Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening., International journal of molecular sciences, 14, (1), 2013, p2085-103
Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Loda M, Mucci LA, Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer., Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 22, (12), 2013, p2354-63
Guevara G, O'Connor E, McCormack O, Harmon M, Finn S, Muldoon C, Ravi N, Reynolds JV, Diffuse oesophageal leiomyomatosis., ANZ journal of surgery, 2013
Mee, B., Gaffney, E., Glynn, S.A., Donatello, S., Carroll, P., Connolly, E., Mc Garrigle, S., Boyle, T., Flannery, D., Sullivan, F.J., McCormick, P., Griffin, M., Muldoon, C., Fay, J., O'Grady, T., Kay, E., Eustace, J., Burke, L., Sheikh, A.A., Finn, S., Flavin, R., Giles, F.J., Development and progress of Ireland's biobank network: Ethical, legal, and social implications (ELSI), Standardized documentation, sample and data release, and international perspective, Biopreservation and Biobanking, 11, (1), 2013, p3-11
Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA, Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG., Journal of the National Cancer Institute, 105, (24), 2013, p1881-90
Doyle SL, Donohoe CL, Finn SP, Howard JM, Lithander FE, Reynolds JV, Pidgeon GP, Lysaght J, IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity., The American journal of gastroenterology, 107, (2), 2012, p196-204
Flavin R, Finn SP, Choueiri TK, Ingoldsby H, Ring M, Barrett C, Rogers M, Smyth P, O'Regan E, Gaffney E, O'Leary JJ, Loda M, Signoretti S, Sheils O, RET protein expression in papillary renal cell carcinoma., Urologic oncology, 30, (6), 2012, p900-5
Fiore C, Bailey D, Conlon N, Wu X, Martin N, Fiorentino M, Finn S, Fall K, Andersson SO, Andren O, Loda M, Flavin R, Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry., Journal of clinical pathology, 65, (6), 2012, p496-502
SL Doyle, C Donohoe, S Finn, J Howard, FE Lithander, JV Reynolds, G Pidgeon, J Lysaght , IGF-1 and its Receptor in Esophageal Cancer: Association with Adenocarcinoma and Visceral Obesity, American Journal of Gastroenterology, 107, 2012, p196 - 204
Penney, K.L., Sinnott, J.A., Fall, K., Pawitan, Y., Hoshida, Y., Kraft, P., Stark, J.R., Fiorentino, M., Perner, S., Finn, S., Calza, S., Flavin, R., Freedman, M.L., Setlur, S., Sesso, H.D., Andersson, S.-O., Martin, N., Kantoff, P.W., Johansson, J.-E., Adami, H.-O., Rubin, M.A., Loda, M., Golub, T.R., Andrén, O., Stampfer, M.J., Mucci, L.A., mRNA expression signature of gleason grade predicts lethal prostate cancer, Journal of Clinical Oncology, 29, (17), 2011, p2391-2396
Dhillon, P.K., Penney, K.L., Schumacher, F., Rider, J.R., Sesso, H.D., Pollak, M., Fiorentino, M., Finn, S., Loda, M., Rifai, N., Mucci, L.A., Giovannucci, E., Stampfer, M.J., Jing, M., Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer, Cancer Epidemiology Biomarkers and Prevention, 20, (12), 2011, p2618-2627
Egan K, Crowley D, Smyth P, O'Toole S, Spillane C, Martin C, Gallagher M, Canney A, Norris L, Conlon N, McEvoy L, Ffrench B, Stordal B, Keegan H, Finn S, McEneaney V, Laios A, Ducrée J, Dunne E, Smith L, Berndt M, Sheils O, Kenny D, O'Leary J, Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells, PLoS ONE, 6, (10, e26125), 2011
Fiorentino, M., Judson, G., Penney, K., Flavin, R., Stark, J., Fiore, C., Fall, K., Martin, N., Ma, J., Sinnott, J., Giovannucci, E., Stampfer, M., Sesso, H.D., Kantoff, P.W., Finn, S., Loda, M., Mucci, L., Immunohistochemical expression of BRCA1 and lethal prostate cancer (Cancer Research (2010) 70, (3136-3139) DOI:10.1158/0008-5472.CAN-09-4100), Cancer Research, 70, (11), 2010
Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA, Genetic variation in RNASEL associated with prostate cancer risk and progression., Carcinogenesis, 31, (9), 2010, p1597-603
Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S, B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression., Proceedings of the National Academy of Sciences of the United States of America, 107, (23), 2010, p10649-54
Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher FR, Mucci LA, Stampfer MJ, Giovannucci E, Loda M, Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival., Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28, (25), 2010, p3958-64
Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Finn S, Loda M, Mucci L, Immunohistochemical expression of BRCA1 and lethal prostate cancer., Cancer research, 70, (8), 2010, p3136-9
Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, Colussi C, Lirangi V, Illi B, D'Eletto M, Cianciulli AM, Gallucci M, De Carli P, Sentinelli S, Mottolese M, Carlini P, Strigari L, Finn S, Mueller E, Arcangeli G, Gaetano C, Capogrossi MC, Donnorso RP, Bacchetti S, Sacchi A, Pontecorvi A, Loda M, Farsetti A, Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer., The Journal of clinical investigation, 119, (5), 2009, p1093-108
Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M, Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer., Journal of the National Cancer Institute, 101, (7), 2009, p519-32
Flavin R, Jackl G, Finn S, Smyth P, Ring M, O'Regan E, Cahill S, Unger K, Denning K, Jinghuan Li Aherne S, Tallini G, Gaffney E, O'Leary JJ, Zitzelsberger H, Sheils O, RET/PTC rearrangement occurring in primary peritoneal carcinoma., International journal of surgical pathology, 17, (3), 2009, p187-97
Flavin R, Smyth P, Barrett C, Russell S, Wen H, Wei J, Laios A, O'Toole S, Ring M, Denning K, Li J, Aherne S, Sammarae D, Aziz NA, Alhadi A, Finn SP, Loda M, B S, Sheils O, O'Leary JJ, miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma., International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 19, (4), 2009, p641-7
Flavin, R., Smyth, P., Barrett, C., Russell, S., Wen, H., Wei, J., Laios, A., O'Toole, S., Ring, M., Denning, K., Li, J., Aherne, S., Sammarae, D., Aziz, N.A., Alhadi, A., Finn, S.P., Loda, M., Sheppard, B., Sheils, O., O'Leary, J.J., MiR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma, International Journal of Gynecological Cancer, 19, (4), 2009, p641-647
Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, Maglathlin RL, Lewis TA, Liau LM, Nghiemphu P, Mellinghoff IK, Louis DN, Loda M, Carr SA, Kung AL, Golub TR, Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy., Nature biotechnology, 27, (1), 2009, p77-83
Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M, Brown M, FOXA1 is a potential oncogene in anaplastic thyroid carcinoma., Clinical cancer research : an official journal of the American Association for Cancer Research, 15, (11), 2009, p3680-9
Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA, Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27, (21), 2009, p3459-64
Wadlow RC, Wittner BS, Finley SA, Bergquist H, Upadhyay R, Finn S, Loda M, Mahmood U, Ramaswamy S, Systems-level modeling of cancer-fibroblast interaction., PloS one, 4, (9), 2009, pe6888
Flavin RJ, Smyth PC, Laios A, O'Toole SA, Barrett C, Finn SP, Russell S, Ring M, Denning KM, Li J, Aherne ST, Sammarae DA, Aziz NA, Alhadi A, Sheppard BL, Lao K, Sheils OM, O'Leary JJ, Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma., Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 22, (2), 2009, p197-205
Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Mermel C, Barretina J, Chan JA, Baselga J, Tabernero J, Root DE, Fuchs CS, Loda M, Shivdasani RA, Meyerson M, Hahn WC, CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity., Nature, 455, (7212), 2008, p547-51
Flavin RJ, Smyth PC, Finn SP, Laios A, O'Toole SA, Barrett C, Ring M, Denning KM, Li J, Aherne ST, Aziz NA, Alhadi A, Sheppard BL, Loda M, Martin C, Sheils OM, O'Leary JJ, Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients., Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 21, (6), 2008, p676-84
O'Regan EM, Toner ME, Finn SP, Fan CY, Ring M, Hagmar B, Timon C, Smyth P, Cahill S, Flavin R, Sheils OM, O'Leary JJ, p16(INK4A) genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas., Human pathology, 39, (3), 2008, p452-8
O'Regan, E.M., Toner, M.E., Finn, S.P., Fan, C.Y., Ring, M., Hagmar, B., Timon, C., Smyth, P., Cahill, S., Flavin, R., Sheils, O.M., O'Leary, J.J., p16INK4A genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas, Human Pathology, 39, (3), 2008, p452-458
Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, Mucci L, Giovannucci E, Finn S, Loda M, Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer., Laboratory investigation; a journal of technical methods and pathology, 88, (12), 2008, p1340-8
Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D'Arcy T, McGuinness E, Sheils O, Sheppard B, O' Leary J, Potential role of miR-9 and miR-223 in recurrent ovarian cancer., Molecular cancer, 7, 2008, p35
Finn SP, Smyth P, Cahill S, Streck C, O'Regan EM, Flavin R, Sherlock J, Howells D, Henfrey R, Cullen M, Toner M, Timon C, O'Leary JJ, Sheils OM, Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy., Virchows Archiv : an international journal of pathology, 450, (3), 2007, p249-60
Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL, Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN., Cancer cell, 11, (6), 2007, p555-69
Nieto M, Finn S, Loda M, Hahn WC, Prostate cancer: Re-focusing on androgen receptor signaling., The international journal of biochemistry & cell biology, 39, (9), 2007, p1562-8
Flavin R, Smyth P, Crotty P, Finn S, Cahill S, Denning K, Jinghuan Li O'Regan E, O'Leary J, Sheils O, BRAF T1799A mutation occurring in a case of malignant struma ovarii., International journal of surgical pathology, 15, (2), 2007, p116-20
O'Brien TP, Walsh MT, Kavanagh EG, Finn SP, Grace PA, McGloughlin TM, Surgical feasibility study of a novel polytetrafluoroethylene graft design for the treatment of peripheral arterial disease., Annals of vascular surgery, 21, (5), 2007, p611-7
Denning KM, Smyth PC, Cahill SF, Finn SP, Conlon E, Li J, Flavin RJ, Aherne ST, Guenther SM, Ferlinz A, O'Leary JJ, Sheils OM, A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples., Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 20, (10), 2007, p1095-102
Finn S, Smyth P, O'Regan E, Cahill S, Toner M, Timon C, Flavin R, O'Leary J, Sheils O, Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines., Archives of pathology & laboratory medicine, 131, (1), 2007, p65-73
Byers RJ, Di Vizio D, O'connell F, Tholouli E, Levenson RM, Gossage K, Gossard K, Twomey D, Yang Y, Benedettini E, Rose J, Ligon KL, Finn SP, Golub TR, Loda M, Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution., The Journal of molecular diagnostics : JMD, 9, (1), 2007, p20-9
O'Regan EM, Toner ME, Smyth PC, Finn SP, Timon C, Cahill S, Flavin R, O'Leary JJ, Sheils O, Distinct array comparative genomic hybridization profiles in oral squamous cell carcinoma occurring in young patients., Head & neck, 28, (4), 2006, p330-8
Guarner J, Bartlett J, Reagan S, Fischer M, Finn S, O'Briain DS, Black M, Hood J, Zaki SR, Immunohistochemical evidence of Clostridium sp, Staphylococcus aureus, and group A Streptococcus in severe soft tissue infections related to injection drug use., Human pathology, 37, (11), 2006, p1482-8
Cahill S, Smyth P, Finn SP, Denning K, Flavin R, O'Regan EM, Li J, Potratz A, Guenther SM, Henfrey R, O'Leary JJ, Sheils O, Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model., Molecular cancer, 5, 2006, p70
Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann J, Febbo P, Loda M, The isopeptidase USP2a protects human prostate cancer from apoptosis., Cancer research, 66, (17), 2006, p8625-32
Flavin R, Finn S, McErlean A, Smyth P, Meaney J, O'Connell F, Kellett J, McGovern E, Gaffney E, Cannonball metastases with favourable prognosis., Irish journal of medical science, 174, (1), 2005, p61-4
Smyth, P., Finn, S., Cahill, S., O'Regan, E., Flavin, R., O'Leary, J.J., Sheils, O., Ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic irish cohort of papillary thyroid carcinoma, International Journal of Surgical Pathology, 13, (1), 2005, p1-8
Smyth P, Finn S, Cahill S, O'Regan E, Flavin R, O'Leary JJ, Sheils O, ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma., International journal of surgical pathology, 13, (1), 2005, p1-8
Finn SP, Smyth P, O'regan E, Cahill S, Flavin R, O'leary J, Sheils O, Array comparative genomic hybridisation analysis of gamma-irradiated human thyrocytes., Virchows Archiv : an international journal of pathology, 445, (4), 2004, p396-404
Sheils, O.M., Finn, S., O'Leary, J.J., Quality-control issues for PCR-based assays in the molecular laboratory , 9, (3), 2003, p165-172
Sheils, O., Finn, S., O'Leary, J., Nucleic acid microarrays: An overview, 9, (3), 2003, pPages 155-158
Finn SP, Leen E, English L, O'Briain DS, Autopsy findings in an outbreak of severe systemic illness in heroin users following injection site inflammation: an effect of Clostridium novyi exotoxin?, Archives of pathology & laboratory medicine, 127, (11), 2003, p1465-70
Smyth P, Finn S, O'Leary J, Sheils O, Real-time analysis of beta- and gamma-catenin mRNA expression in ret/PTC-1 activated and nonactivated thyroid tissues., Diagnostic molecular pathology : the American journal of surgical pathology, part B, 12, (1), 2003, p44-9
Finn, S.P., Smyth, P., O'Leary, J., Sweeney, E.C., Sheils, O., Comment: Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma, Journal of Clinical Endocrinology and Metabolism, 88, (2), 2003, p938-941
Finn SP, Smyth P, O'Leary J, Sweeney EC, Sheils O, Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma., The Journal of clinical endocrinology and metabolism, 88, (2), 2003, p938-41
Murphy SM, Browne RF, Finn S, Myers E, Crotty P, Grainger R, Non-metastatic primitive peripheral neuroectodermal tumour of the kidney (extraskeletal Ewing's sarcoma) with vena caval tumour thrombus., BJU international, 92 Suppl 3, 2003, pe44
SMYTH, P, E-CADHERIN EXPRESSION IS REDUCED IN REVPTC-1 BUT NOT REVPTC-3 ACTIVATED THYROID NEOPLASMS, unknown, 2002, 198, ISI Web of Science, 2002, pp11A - 11A
SHEILS, O, SMYTH, P, FINN, S, SWEENEY, EC, OLEARY, JJ, RET/PTC REARRANGEMENTS IN HASHIMOTO'S THYROIDITIS, INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 10, 2002, 167 - 168
SMYTH, P, ANALYSIS OF BETA-CATENIN EXPRESSION IN THYROID NEOPLASIA, unknown, 2002, 198, ISI Web of Science, 2002, pp49A - 49A
SMYTH, P, SHEILS, O, FINN, S, MARTIN, C, OLEARY, J, SWEENEY, EC, REAL-TIME QUANTITATIVE ANALYSIS OF E-CADHERIN EXPRESSION IN RET/PTC-1-ACTIVATED THYROID NEOPLASMS, INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 9, 2002, p265 - 272
Finn S, Toner M, Timon C, The node-negative neck: accuracy of clinical intraoperative lymph node assessment for metastatic disease in head and neck cancer., The Laryngoscope, 112, (4), 2002, p630-3
SHEILS, OM, IN-VITRO AND IN-VIVO EVIDENCE OF AN ASSOCIATION BETWEEN RET/PTC EXPRESSION AND CELL ADHESIVENESS AND MORPHOLOGY IN THYROID NEOPLASIA, unknown, 2002, 82, ISI Web of Science, 2002, pp120A - 120A
FINN, S, TONER, M, TIMON, C, THE NODE-NEGATIVE NECK: ACCURACY OF CLINICAL INTRAOPERATIVE LYMPH NODE ASSESSMENT FOR METASTATIC DISEASE IN HEAD AND NECK CANCER, LARYNGOSCOPE, 112, 2002, p630 - 633
SHEILS, OM, IN-VITRO AND IN-VIVO EVIDENCE OF AN ASSOCIATION BETWEEN RET/PTC EXPRESSION AND CELL ADHESIVENESS AND MORPHOLOGY IN THYROID NEOPLASIA, unknown, 2002, 15, ISI Web of Science, 2002, pp120A - 120A
FINN, SP, RET/PTC-3 CORRELATES WITH FOLLICULAR/SOLID MORPHOLOGY IN "SPORADIC" PAPILLARY THYROID CARCINOMA, unknown, 2002, 198, ISI Web of Science, 2002, pp50A - 50A
SMYTH, P, E-CADHERIN EXPRESSION IN RET/PTC-1 ACTIVATED THYROID NEOPLASMS, DETECTED BY TAQMAN RT-PCR., unknown, 2001, 195, ISI Web of Science, 2001, pp37A - 37A
FINN, S, SEVERE SYSTEMIC ILLNESS IN HEROIN USERS FOLLOWING INJECTION SITE INFLAMMATION: AUTOPSY FINDINGS IN AN OUTBREAK, unknown, 2001, 81, ISI Web of Science, 2001, pp6A - 6A
FINN, SP, THE N0 NECK: ACCURACY OF CLINICAL INTRA-OPERATIVE LYMPH NODE ASSESSMENT FOR METASTATIC DISEASE IN HEAD AND NECK CANCER., unknown, 2001, 81, ISI Web of Science, 2001, pp150A - 150A
FINN, S, SEVERE SYSTEMIC ILLNESS IN HEROIN USERS FOLLOWING INJECTION SITE INFLAMMATION: AUTOPSY FINDINGS IN AN OUTBREAK, unknown, 2001, 14, ISI Web of Science, 2001, pp6A - 6A
FINN, SP, THE NO NECK: ACCURACY OF CLINICAL INTRA-OPERATIVE LYMPH NODE ASSESSMENT FOR METASTATIC DISEASE IN HEAD AND NECK CANCER, unknown, 2001, 14, ISI Web of Science, 2001, pp150A - 150A
Smyth P, Sheils O, Finn S, Martin C, O'Leary J, Sweeney EC, Real-time quantitative analysis of E-cadherin expression in ret/PTC-1-activated thyroid neoplasms., International journal of surgical pathology, 9, (4), 2001, p265-72
Finn S, Ryan P, Sleeman D, The medical management of masseteric hypertrophy with botulinum toxin., Journal of the Irish Dental Association, 46, (3), 2000, p84-6
Research Expertise
Projects
- Title
- Identifying non-coding RNA repertoires of aggressive Prostate cancer
- Summary
- Abstract: Although there has been significant progress in the basic understanding of why prostate cancer (PCa) arises and how it progresses, these advances, unfortunately, have not translated into a cure and have most often have been disappointing with little benefit to men with aggressive PCa. Clinically relevant biomarkers are lacking and simple prognostication in PCa remains elusive outside of the now decades old pathological Gleason scoring system. Our hypothesis, supported by miRNA data from our laboratories, is that non-coding RNA signatures (including known and novel miRNAs) play a key role in aggressive PCa. In addition, cancer stemness is associated with poor prognosis and aggressive PCa. Therefore, we further hypothesize that non-coding RNA expression profiles, particularly miRNA, are linked to stemness in cancer and a clinically aggressive phenotype. In this application, we aim to model stem cell rich PCa and profile biologically aggressive PCa (high Gleason grade) to identify, in hypothesis neutral experiments, non-coding RNAs associated with aggressive and progressive prostate cancer. miRNAs and their isoMirs will be defined in our holoclone stem cell models and high Gleason score tumours, from the biorepository of the Prostate Cancer Research Consortium (PCRC) in Ireland, and compared to founder cells and indolent prostate cancer respectively. Using advanced bioinformatics we will look for stemness and aggression signatures and use these in a smaller focused panel to assess in relation to outcome in richly and meticulously annotated prostate cancer databases from the Physicians Health Study and Health Professionals Follow Up Study. This study will also uniquely identify ncRNA other than miRNA (piRNA, snoRNA, transcribed ultra-conserved regions) and we expect that these will also contribute to the signatures derived. This study will for the first time provide an in depth profile of isoMirs in prostate cancer. We will also integrate existing and newly undertaken gene expression profiles to examine ncRNA in relation to gene expression patterns and pathways with the aim of deriving integrated ncRNA and mRNA profiles in clinically aggressive PCa. Validation will be performed in independent cohorts and in databases of our collaborators in the United States (Harvard School of Public Health). The latter resource allows us to assess outcome in relation to Prostate cancer specific death rather than PSA failure and is annotated for protein pathway, gene expression profiling and clinical data. Aggressive disease in the Harvard datasets is characterized by the presence of metastases or death from PCa. Finally, in a proof of concept study, we will examine the utility of the profiles discovered to monitor disease progression in circulating tumour cells from patients with aggressive metastatic prostate cancer. With the emergence of ncRNA-based therapeutics there is clear translational potential. The ultimate aim is to translate to the clinic non-coding RNA profiles that can be used to inform treatment options for patients with aggressive prostate cancer.
- Funding Agency
- Prostate Cancer Foundation
- Date From
- 01/01/12
- Date To
- 30/12/14
- Title
- EXPECT Trial: Evasion of immune editing by circulating tumour cells is an exercise-modifiable mechanism underlying aggressive behaviour in obese men with prostate cancer
- Summary
- 1. Abstract 1.1 Background Obesity, known to be associated with a pro-inflammatory, pro-thrombotic humoral milieu, confers a worse prognosis in prostate cancer (PrCa). Circulating tumour cells (CTCs) are identified in the blood in advanced cancer. Their quantitation provides prognostic information. "Cloaking" of CTCs by adherent platelets impedes NK-cell clearance of CTCs from the circulation, enhancing metastatic spread. NK-cell function in blood and in solid organs is quantitatively and qualitatively reduced in obesity. Platelet cloaking may be enhanced in obesity due to the pro-inflammatory, pro-thrombotic state, and may be a mechanism for worse cancer-specific outcomes in this group. Obesity and its biochemical effects may be influenced by lifestyle changes such as exercise. Physical activity reduces levels of systemic inflammatory mediators and so an aerobic exercise intervention may represent an accessible and cost-effective means of ameliorating the pro-inflammatory effects of obesity. 1.2 Objectives To determine whether 1. Platelet cloaking of PrCa CTCs is more prominent in men with obesity than without 2. Regular exercise can improve quality of life (QoL) and ameliorate platelet cloaking 3. The degree of platelet cloaking varies with levels of systemic and primary tumour inflammation and coagulability 4. Expression of an obesity-associated lethality gene signature leads to variation in platelet cloaking 1.3 Setting and Methods This international multicentre prospective study will recruit 200 men with metastatic PrCa, dividing them into exposed and non-exposed groups based on BMI ≥ 25. Participants will be recruited from centres in Dublin (Ireland), Örebro (Sweden) and London (UK), and will be randomized to intervention and comparison groups. Blood samples will be taken at recruitment (T0) and at three (T3) and six months (T6). Project 1: CTCs will be enumerated in the T0 samples. Adherent platelets will be quantified and compared between the exposed and non-exposed groups, and correlated with clinicopathological parameters. Project 2: The intervention group will undertake a regular supervised aerobic exercise programme, whereas the comparison group will not. T3 and T6 blood samples will be assessed for CTC numbers and platelet cloaking. Changes will be compared with the T0 sample and between exposed and non-exposed and intervention and comparison groups. Participants will complete a detailed questionnaire to assess quality of life and other parameters at each visit. Project 3: All blood samples will be assessed for NK-cell number and activation, markers of systemic inflammation, adipokines and serum factors related to platelet activation. The prostate needle core biopsies will be examined microscopically for atrophy and inflammation, by morphology and immunohistochemistry, with particular reference to NK-cells. All variables will be correlated with platelet cloaking. Project 4: NCBs will be assessed for expression of an obesity-associated lethality gene signature (whose genes are known to play a role in obesity or platelet aggregation and coagulation), and correlated with platelet cloaking. 1.4 Impact This study aims to elucidate a potential mechanism by which obesity confers a worse prognosis in PrCa, two increasingly prevalent diseases in the western world. We hope to show that a low-cost, accessible intervention can improve QoL and potentially ameliorate the effects of obesity through alterations in the systemic adipokine and inflammatory mediator profile.
- Funding Agency
- World Cancer Research Fund
- Date From
- 01/01/2014
- Title
- Discovery and Clinical Implementation of Novel Predictive Biomarkers for Enzalutamide therapy
- Summary
- Scientific Abstract: Building on funding secured from Bayer and Astellas to perform a clinical trial (Phase II Study of Radium-223 in Combination with Enzalutamide in progressive Osseous-Predominant Metastatic CRPC) this translational project will discover new mutations in the Androgen Receptor and validate existing candidates in the Androgen Receptor Ligand binding domain (W741C and F876L) for response to Enzalutamide (ENZ) using serial, liquid biopsies, tissue biopsies and rapid autopsy tissues. Critically we will develop these assays for accurate stratification of patients and for use in routine blood samples collected from patients before and during Enzalutamide therapy using cell free circulating DNA and circulating tumour cells allied to massively parallel next generation sequencing.
- Funding Agency
- Irish Cancer Society
- Date From
- 01/01/2014
Recognition
Representations
Chairman Molecular Pathology, Faculty of Pathology, RCPI
Memberships
Fellow of the Royal College of Pathologists